Mosquito-borne disease in Australia: Ross River, dengue, malaria, JEV

Mosquito-borne illness in Australia spans a broad clinical spectrum — from the endemic alphaviruses Ross River virus (RRV) and Barmah Forest virus (BFV), which circulate across the Australian mainland and cause tens of thousands of illnesses each decade, to the flaviviruses including Murray Valley encephalitis (MVE) and Japanese encephalitis virus (JEV), which made its debut as a mainland Australian threat in 2022. For returned travellers, dengue — endemic in Far North Queensland and widespread across tropical Asia and the Pacific — along with chikungunya, Zika, and malaria complete the differential.

The role of general practice is to: (1) consider the diagnosis when clinical features align — fever, rash, arthralgia after outdoor exposure or recent travel; (2) order targeted serology or blood films; (3) notify the relevant state public health unit for every confirmed case; (4) advise on supportive management and mosquito avoidance; and (5) recognise the warning signs that require same-day emergency assessment.

Therapeutic Guidelines (eTG) provides the Australian clinical framework. The Communicable Diseases Network Australia (CDNA) publishes Series of National Guidelines (SoNG) for each notifiable mosquito-borne disease, with regular updates as outbreak patterns evolve.

A. Core clinical — the AU general-practice framework

History

Diagnostic yield depends on asking the right questions from the outset.

Exposure history:

• Residential location — close to waterways, floodplains, wetlands, or known high-activity areas
• Outdoor activities — camping, bushwalking, piggery or abattoir work, farming, water recreation
• Season — late summer and autumn peak for RRV in south-eastern Australia; wet season activity in the north; year-round risk in the tropics
• Accommodation type — screened versus unscreened, air-conditioned, use of bed nets

Travel history (imported infections):

• Countries visited and specific itinerary — urban versus rural, jungle trekking, freshwater swimming
• Malaria prophylaxis — agent used, adherence, and whether completed correctly
• Vaccinations received before departure — JEV, yellow fever
• Timing of symptom onset relative to return (incubation periods: dengue 4–7 days; RRV 3–21 days; malaria 7 days to several months for some Plasmodium vivax strains)

Symptom complex by syndrome:

Syndrome	Distinguishing features
Ross River / Barmah Forest	Symmetric polyarthritis (small joints), fever, maculopapular rash, fatigue
Dengue	Severe headache, retro-orbital pain, severe myalgia, thrombocytopenia
Malaria	Paroxysmal or atypical fever, headache, myalgia, splenomegaly
JEV / MVE	Fever progressing to encephalitis, altered consciousness, seizures
Chikungunya	Dengue-like onset plus severe persistent polyarthritis

Examination

Most arboviral infections produce non-specific findings. Targeted examination includes:

• Temperature — fever is almost universal in the acute phase
• Skin — maculopapular rash distribution; petechiae in dengue; vesicular lesions in Barmah Forest; tourniquet test for dengue (inflate blood-pressure cuff to mid-systolic-diastolic pressure for 5 minutes; ≥10 petechiae per cm² is a positive result)
• Joints — swelling, warmth, and range of movement; distribution is characteristically symmetric and peripheral in RRV/BFV
• Lymph nodes — lymphadenopathy in RRV and dengue
• Abdomen — hepatosplenomegaly in malaria and dengue
• Neurology — altered consciousness, focal signs, neck stiffness are red flags for JEV or MVE and require immediate escalation

Investigations

For suspected RRV or BFV: eTG-recommended serology — RRV IgM and IgG (paired sera). IgM positive indicates recent infection; IgG seroconversion on paired specimens confirms recent infection. A single positive IgG is insufficient — it cannot distinguish recent from past infection. Full blood count (mild leucopenia, thrombocytopenia), LFTs, and CRP or ESR are appropriate supporting investigations.

For suspected dengue: NS1 antigen in the first 7 days; IgM serology from day 5 onwards; PCR in specialist labs for early confirmation. In hospital settings, full blood count at least daily — thrombocytopenia plus rising haematocrit (≥20% from baseline) is the haemorrhagic warning signal.

For suspected malaria: Thick and thin blood films (gold standard; identifies species and quantifies parasitaemia) plus a malaria rapid diagnostic test (antigen-based; useful adjunct but does not replace films). Repeat films at 12–24 hour intervals if initial results are negative and clinical suspicion remains high. Add glucose, urea, electrolytes, creatinine, LFTs, LDH, and FBC.

For suspected JEV or MVE: JEV/MVE-specific serology in serum and CSF; MRI brain (characteristic basal ganglia and thalamic signal change); CSF analysis (lymphocytic pleocytosis, raised protein). Refer immediately to infectious disease and neurology.

B. Australian endemic arboviruses — Ross River and Barmah Forest

Ross River virus is the most common arboviral disease in Australia, with approximately 5,000–7,000 notified cases per year — a figure that substantially underestimates true burden given subclinical disease and under-diagnosis. It is endemic across Australia, with particularly high activity in tropical and subtropical Queensland, coastal New South Wales, the Northern Territory, and Western Australia. Outbreaks in southern states follow wet years that expand waterbird and macropod habitats.

The primary vectors are Culex annulirostris, Aedes vigilax, and Aedes camptorhynchus. The animal reservoir is macropods — kangaroos and wallabies — with humans as incidental, dead-end hosts. Humans cannot transmit the virus back to mosquitoes.

Clinical course: After an incubation of 3–21 days, patients develop fever, profound fatigue, myalgia, and the hallmark symmetric polyarthritis affecting hands, wrists, ankles, and knees. A maculopapular rash on the trunk and limbs occurs in approximately 50% of patients. Lymphadenopathy is sometimes present.

Acute illness typically resolves within 2–6 weeks. However, arthralgia and fatigue persist for months in a significant proportion of patients and occasionally for more than a year. This should be managed as a post-viral musculoskeletal condition with pacing, physiotherapy, and reassurance. Ongoing specialist investigations rarely alter management. Most patients eventually recover fully.

Barmah Forest virus is epidemiologically similar to RRV but less common. The rash tends to be more prominent and can be vesicular rather than maculopapular. Duration of illness is generally shorter than RRV.

Treatment (RRV and BFV): Paracetamol and NSAIDs — ibuprofen or naproxen — are appropriate for arthralgia and fever. Physiotherapy with gentle range-of-motion exercise and hydrotherapy is helpful. Graded pacing for fatigue prevents boom-bust activity cycles. Corticosteroids are generally avoided; they show no clear benefit and may prolong the course. Hydroxychloroquine is occasionally used by rheumatology specialists for refractory prolonged arthralgia; the evidence base is limited and this is off-label.

Queensland Health and NSW Health publish regular RRV activity updates by region and season — check before advising patients travelling within Australia.

C. Dengue, malaria, Japanese encephalitis, and other notifiable infections

Dengue fever

Dengue is locally transmitted in Far North Queensland where Aedes aegypti is established, particularly in Cairns, Townsville, and nearby towns, with outbreaks most years. Four serotypes (DENV 1–4) circulate; secondary infection with a different serotype carries significantly higher risk of severe dengue through antibody-dependent enhancement of infection.

The WHO classifies dengue into dengue without warning signs, dengue with warning signs, and severe dengue. The warning-sign phase typically occurs during defervescence — days 3–7 — when plasma leaks from blood vessels.

Warning signs requiring hospital admission:

• Severe abdominal pain or tenderness
• Persistent vomiting
• Mucosal bleeding — gum bleeding, epistaxis, haematemesis
• Lethargy or restlessness disproportionate to fever
• Rapid fall in platelet count below 100 × 10⁹/L
• Haematocrit rise of 20% or more from baseline
• Hepatomegaly
• Clinical or imaging evidence of pleural effusion or ascites

Treatment is supportive with careful fluid management. Paracetamol is the only safe analgesia — NSAIDs and aspirin are strictly contraindicated due to haemorrhagic risk. No specific antiviral exists. Dengue vaccines (Dengvaxia, Qdenga) have complex seroprior-status requirements and should be discussed with a travel medicine physician.

Japanese encephalitis virus

JEV entered the Australian mainland in February 2022, first detected in piggeries in the Murray-Darling Basin across New South Wales, Victoria, South Australia, and Queensland. By 2024, more than 45 confirmed human cases had been reported with deaths. The Australian Immunisation Handbook documents ATAGI’s expanded vaccination recommendations from 2022.

Groups with expanded JEV vaccine eligibility include piggery, abattoir, and veterinary workers in outbreak local government areas; residents of high-risk local government areas as defined by state health authorities; and travellers to JEV-endemic areas of Asia and the Western Pacific.

Approximately 99% of JEV infections are asymptomatic. Severe encephalitis occurs in 0.1–1% — fever and headache followed by rapidly progressive altered consciousness, rigidity, and seizures. Mortality in severe disease is 25–30%; up to 50% of survivors have permanent neurological sequelae. No specific antiviral exists; management is supportive, with neurological intensive care.

Murray Valley encephalitis

MVE is endemic in northern Australia — the Northern Territory, northern Western Australia, and Far North Queensland — and can spread south during wet years when waterbird populations expand. The vector is Culex annulirostris; the reservoir is waterbirds. Most infections are asymptomatic; severe encephalitis carries approximately 25% mortality and significant long-term morbidity. No vaccine or specific antiviral is available.

Malaria

Australia was declared malaria-free in 1981; every case is imported. Returned travellers from sub-Saharan Africa, Papua New Guinea, Solomon Islands, Indonesia, and the Indian subcontinent account for most cases notified nationally.

Fever in a returned traveller equals malaria until proven otherwise. Do not wait for the classic tertian or quartan fever pattern — Plasmodium falciparum frequently presents atypically. Thick and thin blood films with species identification and parasitaemia quantification, plus a malaria rapid diagnostic test, are required urgently — within hours of presentation.

Repeat blood films at 12–24 hour intervals if initial results are negative and clinical suspicion remains. P. falciparum is a medical emergency: cerebral malaria, severe haemolytic anaemia, acute kidney injury, acute respiratory distress syndrome, and circulatory collapse can progress within hours. Immediate infectious disease consultation is mandatory.

Primaquine and tafenoquine, used for radical cure of P. vivax and P. ovale hypnozoites, require G6PD testing before initiation — haemolysis in G6PD-deficient individuals can be life-threatening. eTG Complete provides current Australian antimalarial treatment protocols.

Mosquito avoidance — universal across all syndromes

HealthDirect and Better Health Channel summarise the core prevention principles:

• DEET 20–50% or picaridin 20% on exposed skin, reapplied per product instructions
• Long sleeves and long pants, especially at peak activity times
• Aedes mosquitoes (dengue, Zika, chikungunya) are active during daylight; Culex and Anopheles are most active dusk to dawn
• Insecticide-treated bed nets in malaria and JEV-endemic areas
• Screened or air-conditioned accommodation
• Permethrin-treated clothing for high-risk environments
• Elimination of standing water (pot-plant saucers, blocked gutters, containers) to remove Aedes breeding sites

D. Australian operations

Notification: Every confirmed mosquito-borne disease is notifiable to the relevant state or territory public health unit. Notifiable conditions include RRV, BFV, JEV, MVE, Kunjin virus, dengue, chikungunya, Zika, malaria, and yellow fever. The National Notifiable Diseases Surveillance System (NNDSS) aggregates national data. Notification triggers public health investigation, vector surveillance, and targeted mosquito control.

MBS items: GP consultations are billed under item 23, 36, or 44 according to time and complexity. Pathology requests for specific arboviral serology, blood films, and malaria rapid diagnostic tests are available through standard pathology services.

PBS prescribing: Antimalarials available on the PBS include atovaquone-proguanil (Malarone) and doxycycline on the General Schedule for chemoprophylaxis; chloroquine on the General Schedule; primaquine on Authority Required for radical cure; tafenoquine (Krintafel) on Authority Required for radical cure; and artemether-lumefantrine (Riamet) on Authority Required for treatment of confirmed malaria.

JEV vaccination access: Imojev and JEspect are available; eligibility for funded vaccine has evolved with outbreak patterns — check current state health authority guidance before advising patients. For travel to endemic Asia, the vaccine is funded under specific occupational and travel-medicine programs.

Pre-travel consultation: Smartraveller provides current country-specific health and safety advice. Consultation with a travel medicine provider is strongly recommended before travel to any malaria-endemic or JEV-endemic region.

E. Special populations

Pregnancy. Malaria in pregnancy carries serious risk — placental sequestration of P. falciparum, severe maternal anaemia, fetal loss, preterm birth, and low birth weight. Chemoprophylaxis in pregnancy requires specialist travel medicine input; agent choice differs by trimester and destination. Zika virus in the first trimester carries risk of congenital Zika syndrome — microcephaly, cerebral calcifications, and other neurological malformations. Counsel women who are pregnant or planning pregnancy to seek specialist advice about travel to Zika-endemic areas. Dengue in pregnancy increases the risk of preterm birth and haemorrhagic complications.

Children. Febrile children returned from malaria-endemic areas require urgent blood films — paediatric falciparum malaria can deteriorate rapidly. Dengue warning signs in children mirror those in adults, but children may present with atypical or subtle features. RRV arthralgia in children is real and can impair school function and physical activity.

Immunocompromised patients. Transplant recipients and patients on biological therapies are at higher risk of severe or atypical presentations across all mosquito-borne pathogens. Specialist infectious disease input for prevention and management is advisable.

Aboriginal and Torres Strait Islander communities. JEV and MVE activity in northern Australia particularly affects communities in the Northern Territory, Far North Queensland, and northern Western Australia. JEV vaccination outreach under expanded ATAGI eligibility specifically targets at-risk communities in these regions. CDNA SoNG guidance includes culturally responsive notification and response frameworks.

When to escalate

Refer for same-day specialist review or emergency assessment in the following situations:

• Fever in any returned traveller from a malaria-endemic area — arrange blood films urgently; immediate infectious disease consultation if P. falciparum confirmed
• Dengue with any warning signs — hospital admission for fluid management and haematological monitoring
• Suspected JEV or MVE — fever with neurological deterioration, altered consciousness, or seizures; urgent infectious disease and neurology assessment; MRI brain
• MVE with encephalitis and altered consciousness — neurological intensive care referral
• Malaria in pregnancy — immediate obstetric and infectious disease input
• Chikungunya with severe persistent polyarthritis beyond 3 months — rheumatology referral
• Persistent post-RRV arthralgia with significant functional impairment beyond 6 months — rheumatology if hydroxychloroquine is being considered
• Any suspected yellow fever — urgent infectious disease consultation

What this article is and is not

This is general health information drawn from current Australian general practice resources — Therapeutic Guidelines (eTG), the CDNA Series of National Guidelines, the Australian Immunisation Handbook, and state health authority guidance. It is not personal medical advice and does not create a doctor–patient relationship. Management of specific cases, including choice of antimalarial agent, timing of notification, and interpretation of serology results, is made with your own GP and treating clinician in the context of the current clinical picture and up-to-date guideline versions.

For Australian consumer resources: HealthDirect — Mosquito-borne illnesses, Better Health Channel, Queensland Health, Smartraveller.

---

Sources cited

1. Therapeutic Guidelines (eTG) — Infectious diseases
2. Australian Immunisation Handbook — Japanese encephalitis vaccine
3. CDNA Series of National Guidelines (SoNG)
4. National Notifiable Diseases Surveillance System (NNDSS)
5. Queensland Health — Mosquito-borne diseases
6. NSW Health — Mosquito-borne disease surveillance
7. HealthDirect — Mosquito-borne illnesses
8. Better Health Channel — Ross River fever
9. Smartraveller (DFAT)
10. WHO — Dengue and severe dengue
11. CDC Yellow Book — Mosquito-borne diseases